Concepedia

Author

Piotr J. Wysocki

Jagiellonian UniversityORCID

Also Known As

Anna Sætersdal, Kensei Yamaguchi, M. Wojtukiewicz, Oddział Chemioterapii, Centrum Onkologii im. prof. Franciszka Łukaszczyka, Bydgoszcz, Polska, Oddział Kliniczny Onkologii, Szpital Uniwersytecki, Kraków, Polska, P J Wysocki, P Wysocki, P. J. Wysocki, P. Wysocki, P.J. Wysocki

293

Publications

2.6K

Citations

26

H-Index

73

Concepts

All Affiliations

Jagiellonian UniversityGreater Poland Cancer CenterThe Maria Sklodowska-Curie National Research Institute of OncologyAsan Medical CenterUniversity of Ulsan
PJ

About

Piotr J. Wysocki is an author at Jagiellonian University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

20

1.4K

2

Health Sciences

3

3

665

3

Arts

1

1

48

4

Engineering

1

1

23

5

Public Health

1

1

48

Piotr J. Wysocki

×

38

Publications

1.8K

Citations

23

H-Index

YearCitations

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez,

The Lancet Oncology

2023

521

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

Thomas Powles, Kobe Yuen, Silke Gillessen,

Nature Medicine

2022

231

BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).

Peter Schmid, Seock‐Ah Im, Anne Armstrong,

Journal of Clinical Oncology

2021

105

Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)

Christopher J. Sweeney, Silke Gillessen, Dana E. Rathkopf,

Cancer Research

2020

62

Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice

Nadzieja Drela, Ahmad Jalili, Rafał Kamiński,

Cancer Immunology Immunotherapy

2004

50

Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations.

Piotr J. Wysocki, Konstanty Korski, Katarzyna Lamperska,

PubMed

2008

48

Risk communication as a core public health competence in infectious disease management: Development of the ECDC training curriculum and programme

Petra Dickmann, Thomas Abraham, Satyajit Sarkar,

Eurosurveillance

2016

48

Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.

Katarzyna Kozar, Rafał Kamiński, Tomasz Świtaj,

PubMed

2003

46

Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial

Joon Young Song, Won Suk Choi, Jung Yeon Heo,

EClinicalMedicine

2023

45

166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study

Patrick Schmid, K.H. Jung, Piotr J. Wysocki,

Annals of Oncology

2022

43

Page 1